Clinical trials: Dysfunction
Erectile Dysfunction
Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction
Erectile problems may lead to anxiety, loss of self-esteem and depression and/or stress. The purpose of this national study was to determine if vardenafil is effective in treating impotent men (erectile dysfunction) and evaluate…
- Trial name
- NCT00661596
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 13 sites in Spain
- Volunteers
- 129 people
- Sponsor
- Bayer
Erectile Dysfunction
Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction
This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction cells (AD-SVF) implantation delivered into the corpus cavernous in patients with Erectile Dysfunction.
- Trial name
- NCT02087397
- Testing
- Liposuction, AD-SVF Cell Injection
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Bradycardia, Heart Failure
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
The purpose of this study is to demonstrate the safety and effectiveness of the VDI UHF-ECG System in the diagnosis of ventricular dyssynchrony when compared to the 12-lead ECG in patients with bradycardia and heart failure…
- Conditions
- Bradycardia, Heart Failure, Ventricular Dysfunction
- Trial name
- SYNC (NCT06641362)
- Testing
- Ultra High Frequency Electrocardiogram (UHF-ECG)
- Where
- 12 sites in United States, Czechia and 1 more
- Volunteers
- 360 people
- Sponsor
- VDI Technologies
Erectile Dysfunction
Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction
This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of TPN171H 5mg, 10mg, 20mg or placebo administered orally in patients with…
- Trial name
- NCT04479917
- Testing
- TPN171H
- Where
- 12 sites in China
- Volunteers
- 255 people
- Sponsor
- Vigonvita Life Sciences
Dementia
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)
The drug, scopolamine, can result in short-term impairments of cognitive function, attention, and memory that resemble those seen in aging and Alzheimer's disease.
- Trial name
- NCT01181310
- Testing
- C: MK-3134 25 mg + Scopolamine 0.5 mg, D: Donepezil 10 mg + Scopolamine 0.5 mg, E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Stress Urinary Incontinence, Sexual Dysfunction
Safety, Efficacy and Usage Compliance of the Silk'n Tightra Device
This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n Tightra device for improvement of sexual functioning, vulvovaginal appearance and reduction of SUI.
- Conditions
- Stress Urinary Incontinence, Sexual Dysfunction, Vulvovaginal Atrophy
- Trial name
- NCT03900143
- Testing
- Tightra vaginal device
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Home Skinovations Ltd.
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
AGED Diagnostics Clinical Validation Study
Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate two investigational blood tests developed by AGED Diagnostics for the…
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Trial name
- NCT07867574
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.
- Trial name
- NCT00754052
- Testing
- Aricept (donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Type 2 Diabetes, Liver Disease
Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk
This clinical trial aims to find out if a digital behavioral program, delivered through the SIPPA digital therapeutics app, can help improve blood sugar control and lower the risk of liver fibrosis in adults with type 2 diabetes…
- Trial name
- SIPPA-QH_HHC-2 (NCT07032311)
- Testing
- Behavioral Treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- SIPPA Solutions INC
Dry Eye, Meibomian Gland Dysfunction
Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction
This study is a multicentric, comparative, randomized, investigator-blinded, in parallel groups study to demonstrate the non-inferiority of Neovis® Total Multi in comparison with Systane® Balance, in terms of improvement of…
- Trial name
- NCT05191771
- Testing
- Neovis Total Multi, Systane Balance
- Volunteers
- 120 people
- Sponsor
- Horus Pharma
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 34 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Dry Eye, Meibomian Gland Dysfunction (Disorder)
Effect of a Dietary Supplement on Gut Microbiota and Ocular Surface Outcomes in Dry Eye Disease
This prospective clinical study investigates whether a dietary supplement product can modulate the gut microbiota and improve ocular surface outcomes in patients with dry eye disease.
- Conditions
- Dry Eye, Meibomian Gland Dysfunction (Disorder), Dry Eye Disease (DED), Dry Eye Disease, Meibomian Gland Disease
- Trial name
- NCT07148271
- Testing
- Dietary Supplement Product
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Varol TUNALI
Alzheimer's Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00814801
- Testing
- Galantamine 16 mg/day, Galantamine 24 mg/day
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Janssen Pharmaceutical K.K.
Brain Injuries, Traumatic
HITT Device Pilot Testing for Traumatic Brain Injury
The purpose of this research study is to collect data from the eyes of traumatic brain injury (TBI) patients. Patients will look at a green target that will measure the fixation of the eye for 30 seconds.
- Trial name
- NCT03249818
- Testing
- HITT device
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rebiscan, Inc.
Meibomian Gland Dysfunction, Dry Eye
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
- Trial name
- NCT03652051
- Testing
- AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 321 people
- Sponsor
- Azura Ophthalmics
Cognitive Disorders
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders
The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.
- Trial name
- NCT04295681
- Testing
- MMH-MAP
- Where
- 22 sites in Russia
- Volunteers
- 246 people
- Sponsor
- Materia Medica Holding
Avascular Necrosis of the Talus, Talar Osteochondral Defect of Ankle
Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)
This is a Humanitarian Device Exemption (HDE) approved device. The purpose of this study is to evaluate the continued safety and probable benefit of the restor3d Total Talus Replacement device in commercial use.
- Conditions
- Avascular Necrosis of the Talus, Talar Osteochondral Defect of Ankle, Talar Dysfunction
- Trial name
- NCT06311331
- Testing
- Total Talus Replacement (TTR)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Restor3D
Mild Cognitive Impairment
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
- Trial name
- NCT02211560
- Testing
- Phosphatidylserine
- Where
- 15 sites in United States, Israel
- Volunteers
- 97 people
- Sponsor
- Enzymotec
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.